{"id":13735,"date":"2019-08-05T07:55:28","date_gmt":"2019-08-05T11:55:28","guid":{"rendered":"https:\/\/medicarereport.org\/?p=13735"},"modified":"2019-08-05T07:55:28","modified_gmt":"2019-08-05T11:55:28","slug":"drugmakers-now-masters-at-rolling-out-their-own-generics-to-stifle-competition","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=13735","title":{"rendered":"Drugmakers Now \u2018Masters\u2019 At Rolling Out Their Own Generics To Stifle Competition"},"content":{"rendered":"<p>(By Jay Hancock and Sydney Lupkin for Kaiser Health News)<\/p>\n<p>When PDL BioPharma\u2019s $40 million blood-pressure medicine faced the threat of a generic rival this year, the company pulled out a little-known strategy that critics say helps keep drugs expensive and competition weak.<\/p>\n<p>It launched its own generic version of Tekturna, a pill taken daily by thousands. PDL\u2019s \u201cauthorized\u201d copycat hit the market in March, stealing momentum from the new rival and protecting sales even though Tekturna\u2019s patent ran out\u00a0last year.<\/p>\n<p>PDL\u2019s version sold for $187 a month versus $166 for the competing generic, made by Anchen Pharmaceuticals, according to Connecture, an information technology firm. PDL\u2019s brand-name Tekturna runs about $208 a month.\u00a0 Continue reading<a href=\"https:\/\/khn.org\/news\/drugmakers-now-masters-at-rolling-out-their-own-generics-to-stifle-competition\/\"> article here&#8230;<\/a><\/p>\n<p>Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.<\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-899\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-300x156.png\" alt=\"\" width=\"300\" height=\"156\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-300x156.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-1024x533.png 1024w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1.png 1600w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Jay Hancock and Sydney Lupkin for Kaiser Health News) When PDL BioPharma\u2019s $40 million blood-pressure medicine faced the threat<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-13735","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/13735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13735"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/13735\/revisions"}],"predecessor-version":[{"id":13736,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/13735\/revisions\/13736"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}